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The phospholamban p.(Arg14del) 
pathogenic variant leads to 
cardiomyopathy with heart failure 
and is unreponsive to standard 
heart failure therapy
tim R. eijgenraam1, Bastiaan J. Boukens2,3, cornelis J. Boogerd4, e. Marloes Schouten1, 
cees W. A. van de Kolk5,6, nienke M. Stege1, Wouter P. te Rijdt7, Edgar T. Hoorntje7,8, 
Paul A. van der Zwaag7, eva van Rooij4, J. peter van tintelen9, Maarten p. van den Berg1, 
peter van der Meer1, Jolanda van der Velden10, Herman H. W. Silljé1 & Rudolf A. de Boer1 ✉
Phospholamban (PLN) plays a role in cardiomyocyte calcium handling as primary inhibitor of sarco/
endoplasmic reticulum Ca2+-ATPase (SERCA). The p.(Arg14del) pathogenic variant in the PLN gene 
results in a high risk of developing dilated or arrhythmogenic cardiomyopathy with heart failure. There 
is no established treatment other than standard heart failure therapy or heart transplantation. In this 
study, we generated a novel mouse model with the PLN-R14del pathogenic variant, performed detailed 
phenotyping, and tested the efficacy of established heart failure therapies eplerenone or metoprolol. 
Heterozygous PLN-R14del mice demonstrated increased susceptibility to ex vivo induced arrhythmias, 
and cardiomyopathy at 18 months of age, which was not accelerated by isoproterenol infusion. 
Homozygous PLN-R14del mice exhibited an accelerated phenotype including cardiac dilatation, 
contractile dysfunction, decreased ECG potentials, high susceptibility to ex vivo induced arrhythmias, 
myocardial fibrosis, PLN protein aggregation, and early mortality. Neither eplerenone nor metoprolol 
administration improved cardiac function or survival. In conclusion, our novel PLN-R14del mouse 
model exhibits most features of human disease. Administration of standard heart failure therapy did 
not rescue the phenotype, underscoring the need for better understanding of the pathophysiology 
of PLN-R14del-associated cardiomyopathy. This model provides a great opportunity to study the 
pathophysiology, and to screen for potential therapeutic treatments.
Phospholamban (encoded by the PLN gene) is a 52-amino acid protein that is present in the sarcoplasmic retic-
ulum (SR) membrane1. PLN plays a crucial role in cardiomyocyte calcium handling by acting as a primary 
regulator of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), which transports calcium from the cyto-
sol into the SR1. In its dephosphorylated state, PLN lowers the affinity of SERCA for Ca2+, thereby inhibiting 
calcium uptake1. Phosphorylation of PLN at serine 16 by protein kinase A (PKA) or threonine 17 by Ca2+/
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calmodulin-dependent protein kinase II (CaMKII) relieves PLN-mediated inhibition of SERCA, thereby increas-
ing SERCA activity and subsequent uptake of calcium1. The PLN-SERCA interaction is essential for contraction 
and relaxation of the heart, and is under the regulation of the β-adrenergic receptor pathway to adapt cardiac 
output to physiological needs1.
Several variants in the PLN gene have been described in heart failure (HF)2. The c.40_42delAGA pathogenic 
variant, a heterozygous deletion of arginine 14 (p.(Arg14del)) of the PLN protein, was originally described in 
a Greek family in 20063. Since then, this pathogenic variant has been identified in the USA4, Canada5, China6, 
Germany7, Spain8 and the Netherlands9. Interestingly, this pathogenic variant was described as a founder muta-
tion in the Netherlands, and was identified in ±14% of Dutch patients with dilated cardiomyopathy (DCM) 
or arrhythmogenic right ventricular cardiomyopathy (ARVC), which translates into thousands of carriers9. 
PLN-R14del carriers have a high risk of developing malignant ventricular arrhythmias (VAs) and HF, and are 
often diagnosed with DCM or ARVC, which, given the presence of biventricular abnormalities, is better referred 
to as arrhythmogenic cardiomyopathy (ACM)3,9–11. The phenotype is typically characterized by ECG abnormal-
ities, including low QRS-potentials and inverted T-waves in precordial leads, myocardial fibrosis and fibrofatty 
replacement, and, ultimately, severe biventricular dysfunction and HF3,9,10. The severity of PLN-R14del-associated 
cardiomyopathy is evidenced by mutation carriers having higher incidences of malignant arrhythmias, premature 
sudden cardiac death (SCD) and cardiac transplantation, as compared to DCM and ARVC patients that do not 
carry this pathogenic variant9.
To date, there is no specific therapeutic treatment for PLN-R14del-related cardiomyopathy, and thus the cur-
rent guidelines for HF12, VAs and SCD13 are applied, although cut-offs for recommendation of ICD implantation 
are more lenient, given the malignant phenotype. Clearly, there is an urgent need to evaluate if treatment could 
slow down or even reverse the severe phenotype. In 2021 we expect the results of the PHOspholamban RElated 
CArdiomyopathy STudy - Intervention (i-PHORECAST; ClinicalTrials.gov NCT01857856). As myocardial fibro-
sis is considered to be an early disease manifestation in this cardiomyopathy7,11,14, the i-PHORECAST study aims 
to test the efficacy of the mineralocorticoid receptor antagonist (MRA) eplerenone, which has been shown to 
exert anti-fibrotic effects15, in reducing disease progression or postponing onset of overt disease in asymptomatic 
mutation carriers.
Studies in human mutation carriers are laborious, expensive and take years before results of a single treatment 
may be evaluated. Therefore, we developed a novel mouse model of the PLN-R14del pathogenic variant. In this 
study, we demonstrate that this mouse model accurately resembles the phenotype of human patients, and is unre-
sponsive to standard HF therapies eplerenone and metoprolol.
Results
PLN-R14Δ/Δ mice exhibit heart failure and premature mortality. We generated mice carrying the 
PLN-R14del pathogenic variant by introducing an additional Pln exon-3 containing the R14del pathogenic vari-
ant, followed by Cre-loxP-mediated recombination to replace the wild-type (WT) Pln exon-3 with the mutant Pln 
exon-3 (Fig. 1A), resulting in offspring carrying one PLN-R14del allele. The offspring of subsequent breeding of 
PLN-R14del mice was born in expected Mendelian ratios. Presence of the PLN-R14del pathogenic variant was 
confirmed by Sanger sequencing of left ventricular (LV) genomic DNA. Furthermore, expression of the WT and/
or mutant allele in the LV of WT, heterozygous (R14Δ/+) and homozygous (R14Δ/Δ) mutant mice was confirmed 
by Sanger sequencing of LV cDNA (Fig. 1B). RNA-Seq demonstrated that all groups had similar total levels of LV 
Pln expression (Supplementary Fig. S1A). Expression of mutant Pln in PLN-R14Δ/Δ mice was similar to expres-
sion of the WT Pln gene in WT mice, and PLN-R14Δ/+ mice had equal expression levels of both WT and mutant 
Pln alleles (Supplementary Fig. S1A), indicating that the mutant allele is not degraded by nonsense-mediated 
decay. Mice were monitored for up to 20 months of age (Fig. 1C). Survival of PLN-R14Δ/+ mice was normal until 
this age. In contrast, PLN-R14Δ/Δ mice demonstrated significantly (p < 0.0001) decreased survival compared to 
WT littermates with a maximum life span of 2 months (n = 13, 54–61 days).
The early mortality of PLN-R14Δ/Δ mice within 2 months, prompted us to determine cardiac function at the 
age of 6 weeks. LV end-diastolic and end-systolic volumes were increased, and stroke volume and ejection faction 
were decreased in PLN-R14Δ/Δ mice as compared to WT controls, indicating ventricular dilatation and contrac-
tile dysfunction (Fig. 1D–H). At this age, no cardiac structural and functional abnormalities were observed upon 
MRI in PLN-R14Δ/+ mice.
PLN-R14Δ/Δ mice demonstrate severe cardiac remodeling. To evaluate the effects of the 
PLN-R14del pathogenic variant on cardiac gene expression levels, RNA-Seq was performed on LV tissue of 3- 
and 8-week-old WT, PLN-R14Δ/+ and PLN-R14Δ/Δ mice. Principal component analysis revealed 3 groups with 
distinct gene expression profiles (Fig. 2A). Most notably, 8-week-old PLN-R14Δ/Δ mice clustered and segregated 
from other samples on the first principle component (PC1; Fig. 2A). In contrast, at 3 weeks of age, PLN-R14Δ/Δ 
mice clustered together with WT controls. This is in line with cardiac functional and histological analysis at this 
age, which showed no differences between PLN-R14Δ/Δ mice and WT controls (Supplementary Fig. S2A–E). 
Functional annotation of genes contributing to variance in PC1 (Fig. 2A x-axis, accounting for 78% of variance 
across samples) indicated a strong increase in fibrosis-related gene expression in 8-week-old PLN-R14Δ/Δ mice 
hearts (Supplementary Fig. S1B). Furthermore, PLN-R14Δ/+ mice clustered together with WT mice at 8 weeks 
of age, which showed a more mature cardiac profile compared to 3-week-old hearts (Fig. 2A; PC2) (e.g. elevated 
expression of genes encoding contractile (sarcomeric) proteins, and genes encoding enzymes for β-oxidation), 
whereas PLN-R14Δ/Δ mice showed a less mature profile, including the upregulation of foetal genes in response to 
cardiac dysfunction (Fig. 2A and Supplementary Fig. S1B). Analysis of LV gene expression by qPCR confirmed 
elevated expression of atrial and brain natriuretic peptide genes, Nppa (ANP) and Nppb (BNP), respectively, 
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and an increase in the ratio of beta (Myh7) to alpha (Myh6) myosin heavy chain (MHC) gene expression in 
8-week-old PLN-R14Δ/Δ mice, indicative for activation of the cardiac foetal gene program (Fig. 2B).
Histological analysis of cardiac tissue at 8 weeks of age using Masson’s trichrome staining showed no dif-
ference in fibrosis between WT and PLN-R14Δ/+ mice, whereas in PLN-R14Δ/Δ mice extensive myocardial 
fibrosis was present throughout the LV and right ventricle (RV) (Fig. 2C,D). Elevated LV expression of fibrotic 
genes in PLN-R14Δ/Δ mice was confirmed by qPCR analysis of collagens (Col1a1, Col1a2, Col3a1), galectin-3 
(Lgals3), tissue inhibitor of metalloproteinase 1 (Timp1), and matrix metalloproteinase 2 (Mmp2)16 (Fig. 2E,F). 
Notably, at 3 weeks of age, no differences in myocardial fibrosis were identified between WT and PLN-R14Δ/Δ 
mice (Supplementary Fig. S2E,F). Because histology of cardiac tissues of PLN-R14del patients not only revealed 
extensive scarring, but also aggregation of PLN protein10, we also performed immunofluorescent staining of PLN 
in mouse cardiac sections. This revealed extensive aggregation of PLN proteins in all PLN-R14Δ/Δ mice at 8 weeks 
Figure 1. Generation, validation, survival and cardiac MRI of PLN-R14del mutant mice. (A) Schematic 
overview of the genomic DNA encoding the murine Pln gene, and the modifications that were performed 
to replace the WT Pln exon-3 with the R14del Pln exon-3 (marked with 3*). (B) Fluorescent peak trace 
chromatograms of Sanger sequencing reactions including the coding region of the Pln gene in hearts of WT, 
PLN-R14Δ/+ and PLN-R14Δ/Δ mice. The codon for the 14th amino acid of the PLN protein is outlined by the 
grey rectangle. (C) Survival curve of male and female WT, PLN-R14Δ/+ and PLN-R14Δ/Δ mice (n = 6, 10 and 
13, respectively). (D) Representative cardiac MRI images at the mid-papillary level in end-diastole and end-
systole (scale bar = 1 mm) with quantification of left ventricular end-diastolic volume (E), end-systolic volume 
(F), stroke volume (G), and ejection fraction (H) of 6-week-old WT, PLN-R14Δ/+ and PLN-R14Δ/Δ mice (n = 4, 
5, and 5, respectively). Data are presented as mean ± S.E.M. *p < 0.05 compared to WT (Mann-Whitney test).
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of age (Fig. 2G). Quantification showed that 74.8 ± 2.7% (n = 4) of the cardiomyocytes of PLN-R14Δ/Δ hearts con-
tained aggregates, whereas no such aggregation was present in WT (n = 3) and PLN-R14Δ/+ (n = 5) mice. Western 
blot of LV lysates confirmed the presence of RIPA-insoluble PLN proteins in PLN-R14Δ/Δ hearts (Fig. 2H). As 
Figure 2. Histological and molecular analysis of PLN-R14del mice hearts. (A) Principal component analysis 
plot of RNA-Seq analysis of left ventricles of WT, PLN-R14Δ/+ and PLN-R14Δ/Δ mice of 3 or 8 weeks of age 
(n = 4 per group). 95% confidence ellipses of clusters are marked in grey. Information on genes contributing 
to variance in principle component 1 (PC1, x-axis) and principle component 2 (PC2, y-axis) is shown in 
Supplementary Fig. 1B. (B) qPCR measurements of left ventricular mRNA levels of Nppa (ANP), Nppb (BNP), 
and the ratio of Myh7 (β-MHC) to Myh6 (α-MHC) of 8-week-old WT, PLN-R14Δ/+ and PLN-R14Δ/Δ mice 
(n = 4, 5, and 5, respectively). (C) Representative images of left ventricular sections stained with Masson’s 
trichrome (scale bar = 70 μm) with (D) quantification of myocardial fibrosis in WT, PLN-R14Δ/+ and PLN-
R14Δ/Δ mice hearts (n = 4, 5, and 5, respectively). (E,F) qPCR measurements of left ventricular mRNA levels 
of cardiac remodelling genes Col1a1, Col1a2, Col3a1, Lgals3 (Gal-3), Timp1, and Mmp2 of 8-week-old WT, 
PLN-R14Δ/+ and PLN-R14Δ/Δ mice (n = 4, 5, and 5, respectively). (G) Representative images of left ventricular 
sections of 8-week-old WT, PLN-R14Δ/+ and PLN-R14Δ/Δ mice stained with an anti-PLN antibody (red), 
wheat-germ agglutinin (WGA) (green), and DAPI (blue) (scale bar = 35 μm). (H) Western blot analysis of 
monomeric PLN proteins in RIPA-soluble and RIPA-insoluble fractions of left ventricles of 8-week-old WT 
and PLN-R14Δ/Δ mice (n = 1 and 2, respectively). Images zoom in on the protein bands. Full blot images are 
presented in Supplementary Fig. S3. Gene expression values are corrected for Rplp0 (36B4) gene expression, and 
shown as fold change compared to age-matched WT. Myocardial fibrosis is presented as fold change compared 
to age-matched WT. Data are presented as mean ± S.E.M. *p < 0.05 compared to WT (Mann-Whitney test).
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expected, the soluble housekeeping protein glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was almost 
exclusively present in the RIPA-soluble fraction. Presence of low amounts of GAPDH in the RIPA-insoluble 
fraction is likely explained by contamination with the RIPA-soluble supernatant. At 3 weeks of age, PLN proteins 
were still mostly soluble in the PLN-R14Δ/Δ mice hearts (Supplementary Fig. S2H).
PLN-R14Δ/+ mice develop cardiomyopathy at a later age. As indicated above, PLN-R14Δ/+ mice 
did not show any cardiac abnormalities at 8 weeks of age. However, long term follow-up demonstrated that 
in PLN-R14Δ/+ mice, although LV diameter was comparable to age-matched WT controls (Fig. 3A,B), frac-
tional shortening and global longitudinal strain were significantly (p < 0.05) impaired after 18 months of age 
(Fig. 3C,D). At the age of 20 months, mice were sacrificed, and in line with the echocardiographic findings, LVs 
of PLN-R14Δ/+ mice demonstrated higher gene expression levels of the cardiac foetal gene program (Fig. 3E). 
In addition, cardiac sections of PLN-R14Δ/+ mice showed PLN protein aggregation in some of the cardiomyo-
cytes (on average 7.3 ± 0.9 aggregates/mm2 (n = 10)), whereas this was not observed in age-matched WT hearts 
(n = 6) (Fig. 3F). Furthermore, there was a significant (p < 0.01) increase of myocardial fibrosis in cardiac sec-
tions of PLN-R14Δ/+ mice (Fig. 3G,H). Consistently, fibrotic gene expression levels were elevated in the LVs of 
PLN-R14Δ/+ mice (Fig. 3I,J).
Since PLN-R14Δ/+ mice developed a more subtle phenotype than PLN-R14Δ/Δ mice, and at a later age, we 
investigated whether stimulation of the β-adrenergic pathway, in which PLN plays a role, using isoproterenol 
infusion, could accelerate disease onset in PLN-R14Δ/+ mice. Expectedly, isoproterenol infusion increased heart 
rate, and resulted in cardiac hypertrophy (20% increased heart weight) and cardiac fibrosis (4.5-fold) com-
pared to non-stimulated mice, but there was no difference between PLN-R14Δ/+ and WT stimulated groups 
(Supplementary Fig. S5).
PLN-R14del mice are prone to develop ventricular arrhythmias ex vivo. Besides the DCM phe-
notype, the development of VAs is another key feature of PLN-R14del cardiomyopathy in human patients9. ECG 
recordings of 6-week-old animals did not reveal any differences in heart rate between the different groups, nor 
in PR- and QT-interval and QRS-duration. However, QRS-amplitude was significantly (p < 0.05) diminished in 
PLN-R14Δ/Δ mice compared to WT controls (Fig. 4A,B). This is also considered as one of the first signs of cardiac 
disease in human mutation carriers3,7. We did not detect VAs in these mice during continuous in vivo monitoring 
with a telemetry device in the last month prior to the endpoint (presence of symptoms of severe HF). Since mice 
are in general very resilient to VAs, we tested whether arrhythmias could be induced using ex vivo programmed 
electrical stimulation during Langendorff perfusion. In isolated hearts, conduction velocity measured during cen-
tral stimulation was lower in PLN-R14Δ/+ (3 months of age) and PLN-R14Δ/Δ (6 weeks of age) mice as compared 
to age-matched WT controls, which were combined into a single control group since there were no differences 
between 6-week-old and 3-months-old WT mice (Fig. 4C,D). Action potential duration was not different. The 
incidence of induced VAs was higher in PLN-R14Δ/+ (2/4, p = 0.056) and PLN-R14Δ/Δ (5/6, p < 0.05) mice hearts 
than in WT controls (1/7) (Fig. 4E–G). Thus, under conditions of ex vivo burst pacing both PLN-R14Δ/+ and 
PLN-R14Δ/Δ mice show a much higher propensity for VAs.
PLN-R14Δ/Δ mice are unresponsive to standard heart failure therapy. PLN-R14Δ/Δ mice showed 
similar cardiac characteristic as human patients, and in a timeframe that provides opportunities for therapeutic 
testing. We therefore investigated whether administration of the MRA eplerenone, which has been shown to 
inhibit cardiac fibrosis15, or the β1-adrenergic receptor blocker metoprolol would attenuate disease progression. 
Drug administration was initiated at weaning when PLN-R14Δ/Δ mice were 3 weeks of age, and cardiac abnor-
malities were still absent (Supplementary Fig. S2), and continued until the endpoint (presence of symptoms of 
severe HF) was reached. Similar to the initial phenotyping, in vivo cardiac analysis was performed at the age of 
6 weeks. Efficacy of eplerenone administration was confirmed by increased kidney Ren (renin) gene expres-
sion compared to untreated PLN-R14Δ/Δ mice, reflecting a reported feedback mechanism17 (Supplementary 
Fig. S6A). As expected, metoprolol significantly (p < 0.05) decreased heart rate (Supplementary Fig. S6B). Neither 
eplerenone nor metoprolol administration increased the survival of PLN-R14Δ/Δ mice (Fig. 5A). Furthermore, 
although eplerenone reduced ventricular dilatation, neither treatment prevented contractile dysfunction or car-
diac remodelling (Fig. 5B–F).
Discussion
We demonstrated that the newly generated PLN-R14del mouse model closely mimics the human phenotype 
of PLN-R14del-related cardiomyopathy. We observed a delayed onset of cardiomyopathy in PLN-R14Δ/+ mice, 
including impaired cardiac contractile function after 18 months of age, increased myocardial fibrosis, and the 
presence of PLN protein aggregation. This is consistent with the observations in human mutation carriers, which 
most often present with HF symptoms at middle age9. Furthermore, the hearts of PLN-R14Δ/+ mice were more 
susceptible to develop induced arrhythmias ex vivo, even at an early age when other cardiac abnormalities were 
absent. In contrast to the DCM phenotype that is often found in human patients, PLN-R14Δ/+ mice exhibited no 
ventricular dilatation. As dilatation may be secondary to contractile dysfunction, cardiac dilatation may occur at 
a later stage. However, longer follow up would be needed to confirm this.
Cohort screenings have reported to identify the PLN-R14del pathogenic variant in up to 1:200 of included 
patients, which translates to thousands of mutation carriers18,19. However, so far only 1,000 carriers have been 
identified, and clinical heterogeneity has been observed, suggesting that additional factors may contribute to 
the disease onset and severity. In this study, we demonstrated that stimulation of the β-adrenergic pathway, in 
which PLN plays a role, could not accelerate disease onset in PLN-R14Δ/+ mice, suggesting that β-adrenergic 
6Scientific RepoRtS |         (2020) 10:9819  | https://doi.org/10.1038/s41598-020-66656-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
Figure 3. Cardiac functional, histological and molecular analysis of 12- to 20-month-old PLN-R14Δ/+ mice. 
Echocardiographic analysis of left ventricular end-diastolic diameter (A), end-systolic diameter (B), fractional 
shortening (C), and global longitudinal strain (D) of 12-, 18- and 20-month-old WT and PLN-R14Δ/+ mice 
(n = 9, 10, 6, 10, 5 and 9, respectively). (E) qPCR measurements of left ventricular mRNA levels of Nppa (ANP), 
Nppb (BNP), and the ratio of Myh7 (β-MHC) to Myh6 (α-MHC) of 20-month-old WT and PLN-R14Δ/+ mice 
(n = 6 and 10, respectively). (F) Representative images of left ventricular sections of 20-month-old WT and 
PLN-R14Δ/+ mice stained with an anti-PLN antibody (red), wheat-germ agglutinin (WGA) (green), and DAPI 
(blue) (scale bar = 35 μm) or (G) stained with Masson’s trichrome (scale bar = 70 μm) with (H) quantification 
of myocardial fibrosis (n = 6 and 9, respectively). (I,J) qPCR measurements of left ventricular mRNA levels of 
cardiac remodelling genes Col1a1, Col1a2, Col3a1, Lgals3 (Gal-3), Timp1, and Mmp2 of 20-month-old WT 
and PLN-R14Δ/+ mice (n = 6 and 10, respectively). Gene expression values are corrected for Rplp0 (36B4) gene 
expression, and shown as fold change compared to age-matched WT. Myocardial fibrosis is presented as fold 
change compared to age-matched WT. Data are presented as mean ± S.E.M. *p < 0.05, **p < 0.01, ***p < 0.001 
compared to age-matched WT (Mann-Whitney test).
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stimulation may not influence the disease. Investigating the effect of different disease modifiers in PLN-R14Δ/+ 
mice could identify risk factors for this type of cardiomyopathy.
In addition to the findings in PLN-R14Δ/+ mice, we observed that PLN-R14Δ/Δ mice exhibited the same 
cardiac phenotype as human cardiomyopathy patients that carry this pathogenic variant, but in an accelerated 
manner. Indeed, until now, mutations carriers have been found to be heterozygous for this pathogenic variant3–9. 
We speculate that the presence of only the PLN-R14del protein, in the absence of the PLN-WT protein, accel-
erates the detrimental effects of the pathogenic variant (as seen in PLN-R14Δ/Δ mice), whereas in PLN-R14Δ/+ 
mice, where equal amounts of PLN-WT and PLN-R14del are present, the disease onset is at a later age. It has been 
reported that cardiomyocytes independently transcribe both alleles of a gene, and that individual cells might 
favour expression of one allele over the other20. Possibly, the expression level or accumulation of the PLN-R14del 
protein has to exceed a certain threshold to trigger cardiomyopathy. Thus, even in heterozygous individuals, 
not only SERCA superinhibition may occur but also loss of inhibition and PLN-R14del aggregation. This could 
contribute to the clinical heterogeneity that is observed in mutation carriers, and may also explain why in cardiac 
tissues of patients a mosaic pattern of cardiomyocytes with and without PLN aggregation is observed. The latter 
is also true for our PLN-R14Δ/+ mice.
Figure 4. Electrophysiological characterization of PLN-R14del mice hearts. (A) Representative averaged 
views of 1-minute in vivo ECG measurements of 6-week-old WT, PLN-R14Δ/+ and PLN-R14Δ/Δ mice with (B) 
quantification of total QRS-complex (peak-to-peak) amplitude (n = 4, 5, and 5, respectively). (C) Reconstructed 
activation maps during ex vivo left ventricular stimulation (120 ms interval) with (D) quantification of 
longitudinal conduction velocity in WT, PLN-R14Δ/+ and PLN-R14Δ/Δ mice hearts (n = 6, 4, and 5, 
respectively). (E) Incidence of ex vivo induced ventricular arrhythmias in WT, PLN-R14Δ/+ and PLN-R14Δ/Δ 
mice hearts (n = 7, 4, and 7, respectively). (F) Example of a pseudo-ECG (upper) with simultaneously recorded 
optical action potentials (OAPs) (middle), and reconstructed activation maps (lower) from a WT mouse, which 
indicates the order of activation from several beats that correspond to the traces above (indicated by the small 
letter). (G) Pseudo-ECG showing an induced arrhythmia in a PLN-R14Δ/Δ mouse heart following burst pacing. 
Data are presented as mean ± S.E.M. *p < 0.05 compared to WT (Mann-Whitney test).
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As there is no specific therapy for PLN-R14del-related cardiomyopathy, current HF guidelines, which recom-
mend treatment with angiotensin-converting enzyme (ACE) inhibitors, beta-blockers and MRAs or a combina-
tion, are applied for treatment12. Since the accelerated phenotype of PLN-R14Δ/Δ mice allows for rapid therapeutic 
drug screening, we tested whether PLN-R14Δ/Δ mice would benefit from standard HF therapy by administering 
eplerenone or metoprolol, which have been shown to have therapeutic effects in heart failure15,21. Drug adminis-
tration was initiated at an early age when cardiac abnormalities were still absent in PLN-R14Δ/Δ mice to examine 
whether these drugs would attenuate disease development. Eplerenone administration resulted in decreased LV 
volume, most likely related to its diuretic effect and subsequent unloading of the heart. However, neither drug 
could prevent disease development or increase survival. The finding that inhibition of the β-adrenergic pathway 
does not prevent disease progression in PLN-R14Δ/Δ mice is in line with the finding that stimulation of this 
pathway does not accelerate the phenotype of PLN-R14Δ/+ mice. These results show that common HF drugs 
could not attenuate the progression towards end-stage HF in this accelerated model. In humans, fortunately, such 
fast-forward presentations are rare, but in some patients, deterioration is very fast, which cannot be rescued by 
common guideline recommended drugs, in line with our findings. On the other hand, many patients present with 
more slowly progressive disease, and common HF drugs may attenuate progression. Our results do not exclude 
such a long-term beneficial effect.
Previously, Haghighi et al.3 have generated a heterozygous PLN-R14del mouse model with cardiac-specific 
overexpression of the murine PLN-R14del protein under control of the α-MHC promoter in the presence of 
endogenous PLN-WT. Overexpression of PLN-R14del resulted in superinhibition of SERCA, associated with 
cardiac hypertrophy, myocardial fibrosis, and premature death between 2 and 16 weeks of age. Later, the same 
group has also overexpressed PLN-R14del in a PLN-KO background (analogous to homozygous PLN-R14del 
expression)22. Although this model did not exhibit increased mortality, it exerted a similar cardiac phenotype at 
3 months of age. However, PLN-R14del alone, in the absence of PLN-WT, was unable to inhibit SERCA, and was 
found to inhibit the Na+/K+-ATPase at the plasma membrane, implicating mechanistic differences. In contrast, 
Figure 5. Effect of administration of eplerenone or metoprolol on survival and cardiac function of PLN-
R14Δ/Δ mice. (A) Survival curve of WT and PLN-R14Δ/Δ mice without or with eplerenone (EPLE; 200 mg/
kg/day) or metoprolol (METO; 350 mg/kg/day) administration (n = 11, 12, 12, and 10, respectively). (B–E) 
Echocardiographic analysis of left ventricular end-diastolic and end-systolic diameter, fractional shortening, 
and global longitudinal strain of 6-week-old WT and PLN-R14Δ/Δ mice without or with eplerenone or 
metoprolol administration (n = 11, 12, 12, and 10, respectively). (F) Quantification of myocardial fibrosis in 
Masson’s trichrome-stained left ventricular sections of 16-week-old WT and 8-week-old PLN-R14Δ/Δ mice 
without or with eplerenone or metoprolol administration (n = 11, 12, 12, and 10, respectively). Myocardial 
fibrosis is presented as fold change compared to age-matched WT. Data are presented as mean ± S.E.M. 
*p < 0.05, ****p < 0.0001 compared to WT; #p < 0.05, ##p < 0.01 compared to R14Δ/Δ + VEH (one-way 
ANOVA followed by Tukey’s post-hoc test).
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our novel mouse model was generated by editing the murine genome to endogenously express PLN-R14del. We 
believe that this more accurately resembles the situation of human disease and provides normal endogenous lev-
els of PLN-WT and PLN-R14del (which were present in equal amounts in PLN-R14Δ/+ mice hearts) rather than 
the classical method of (over)expressing PLN-R14del on top of endogenous PLN-WT. Accordingly, the cardiac 
phenotype of our model, which represents DCM with inducible arrhythmias, has specific aspects that are closer 
to the human disease phenotype than the models of Haghighi et al., which mostly revolve around cardiac hyper-
trophy, but lacked cardiac functional and electrophysiological data3,22. Additionally, similar to human patients, we 
demonstrate PLN protein aggregates in the cardiomyocytes of this model, while this has not been demonstrated 
in other models. Finally, we have investigated the propensity towards VAs, which is an important part of the dis-
ease. Electrophysiological properties of the murine heart are different from the human, and spontaneous VAs are 
rare in mice, but we show that both PLN-R14Δ/+ and PLN-R14Δ/Δ mice hearts were prone to develop VAs upon 
electrical stimulation. Although we did not study the relation between altered conduction and other electrophys-
iological differences in detail, the observed inducibility of VAs was also present at an early age and in the absence 
of extensive myocardial fibrosis, a known substrate for conduction irregularities23, which is suggestive of aber-
rant calcium handling. As mentioned above, Haghighi et al. reported mechanistic differences between mice with 
heterozygous and homozygous PLN-R14del overexpression3,22. However, we clearly observed a ‘dose-dependent’ 
effect with regards to the amount of mutant PLN, i.e. the phenotype of PLN-R14Δ/Δ mice was far more severe 
than in PLN-R14Δ/+ mice, suggesting that the more mutant PLN is present, the more severe phenotype develops. 
Likely, this difference is the result of the different methods that were used to generate the mouse models.
Te Rijdt et al.10 demonstrated that the PLN protein aggregates colocalized with autophagy markers p62 and 
microtubule-associated protein light chain 3 (LC3), suggesting that the protein quality control (PQC) system, 
the cell’s endogenous system to control correct protein folding, is unable to resolve the protein aggregates. 
Aggregation of PLN proteins in the cardiomyocytes and insufficiency of the PCQ system to correct this, could 
play a causal role in the pathophysiology of PLN-R14del-related cardiomyopathy. Aggregation of PLN proteins 
likely affects the effect of PLN on SERCA. It is well known that protein aggregation is involved in several neurode-
generative diseases, such as Alzheimer’s, Parkinson’s, and Huntington’s disease24, and it is becoming increasingly 
recognized that impairment in protein homeostasis and protein aggregation also play a role in HF, including 
hypertrophic25, dilated26, and desmin-related cardiomyopathy (desminopathy)27, ischemic28 and diabetic29 heart 
disease, and HF with preserved ejection fraction (HFpEF)30. Future experiments should define the contribution 
of protein aggregation and disturbed calcium handling to the development of PLN-R14del-related cardiomyo-
pathy. Further, enhancement of the PQC system has been reported to be beneficial in multiple models of HF31–33, 
and boosting the PQC system may be explored as a novel therapeutic approach.
In conclusion, we have generated a novel mouse model carrying the PLN-R14del pathogenic variant, and 
PLN-R14Δ/Δ mice mimic human disease in a strikingly comparable but accelerated manner, whereas PLN-R14Δ/+ 
mice exhibit cardiomyopathy at middle age similar to human carriers (Fig. 6). Administration of standard HF 
therapy does not rescue the phenotype, underscoring the need for better understanding of the pathophysiol-
ogy of PLN-R14del-related cardiomyopathy, and PLN-targeted therapy. This model will be useful for a better 
understanding of cardiomyopathies that are primarily caused by PLN pathogenic variants or with secondary PLN 
abnormalities, and for screening of secondary disease modifiers and potential therapeutic treatments.
Methods
Detailed descriptions of the methods are available in the Supplementary Information.
Animals. All animal experiments were approved by the animal ethical committee of the University of 
Groningen (permit numbers AVD10500201583, IVD1583-02-001, IVD1583-02-004, IVD1583-02-009 and 
IVD1583-05-002), and were performed conform the existing guidelines for the care and use of laboratory ani-
mals. To generate mice with the PLN-R14del pathogenic variant, a C57Bl6/N mouse line was generated, in which 
the third exon of the murine Pln gene, which contains the coding region for the PLN protein, was flanked by loxP 
sites (floxed) and followed by a third exon of the murine Pln gene with the c.40_42delAGA pathogenic variant 
(performed by PolyGene, Switzerland). To delete the floxed region, these mice were bred with mice expressing 
the Cre enzyme in the germline under the control of the hypoxanthine-guanine phosphoribosyltransferase (Hprt) 
promoter enhancer, replacing the murine WT Pln exon-3 with the murine R14del Pln exon-3 in the resulting 
offspring (Fig. 1A).
Sanger sequencing. Total RNA was isolated from cardiac tissues using TRI Reagent (Sigma-Aldrich, MO, 
USA), and cDNA synthesis was performed using QuantiTect reverse transcription kit (Qiagen, Germany) as pre-
viously described34. Total genomic DNA was isolated from cardiac tissues using the DNeasy Blood & Tissue kit 
(Qiagen). DNA fragments for Sanger sequencing were generated by PCR of cDNA and genomic DNA using Taq 
DNA Polymerase (Roche Diagnostics, Switzerland). PCR products were purified using agarose gel electropho-
resis. Fragments of the correct length were excised and isolated using the QIAquick Gel Extraction kit (Qiagen). 
Sanger sequencing was performed by GATC-Biotech (Germany).
RNA-Seq analysis. Total RNA was isolated from LV tissues using TRI Reagent (Invitrogen, CA, USA). RNA 
quality was determined using RNA Pico Chips on a 2100 Bioanalyzer system (Agilent, CA, USA), and TruSeq 
Stranded mRNA libraries (Illumina, CA, USA) were generated from high quality (RIN > 8.0) total RNA. Samples 
were subjected to single-end sequencing using a NextSeq. 500 sequencer (Illumina). Reads were aligned to 
mouse reference genome (mm10) using spliced transcript alignment to a reference (STAR, version 2.4.2a)35, and 
readcount analysis was performed using the HTSeq package (version 0.6.1) in Python36. Differential expression 
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analysis was performed using the DESeq. 2 package (version 1.24.0) in R37. Gene set enrichment analysis was 
performed using fgsea package (version 1.10.0) in R38 with the MSigDB database (version 6.2)39.
Cardiac magnetic resonance imaging. Cardiac MRI measurements were performed using an AVANCE 
400 MR system (Bruker BioSpin, Germany) as previously described40. Volumetric analyses were performed using 
cvi42 software (version 5.6.6, Circle Cardiovascular Imaging, Canada).
Echocardiography. Echocardiographic measurements were performed using a Vevo 3100 preclinical 
imaging system, equipped with a 40-MHz MX550D linear array transducer (FUJIFILM VisualSonics, Canada). 
General techniques were reported before41. Vevo LAB software (version 3.1.1; FUJIFILM VisualSonics) was used 
to assess cardiac morphology and function.
Surface electrocardiography. ECG recordings were acquired using two-lead subdermal needle electrodes, 
connected to a PowerLab 8/30 data acquisition device (model ML870; ADInstruments, Australia) and an animal 
Bio Amp biological potential amplifier (model ML136; ADInstruments) as previously reported42. Analysis was 
performed using LabChart Pro software (version 8; ADInstruments).
Implantable ECG telemetry. Mice were subcutaneously implanted with telemeter transmitters (ETA-F10; 
Data Sciences International, MA, USA), and the electrode leads were subcutaneously secured in a lead II config-
uration as reported elsewhere43. Continuous ECG recordings in conscious mice were acquired for 3 weeks, and 
analysed using Ponemah software (version 6.41; Data Sciences International).
Isoproterenol infusion. Following initial phenotyping, adult (10-week-old) PLN-R14Δ/+ mice and 
their WT littermates were randomly subjected to infusion of isoproterenol (30 mg/kg/day for 4 weeks; I6504 
Sigma-Aldrich) using subcutaneously implanted ALZET osmotic mini pumps (model 2004; DURECT 
Corporation, CA, USA) or sham surgery as previously described44.
Eplerenone and metoprolol administration. Following initial phenotyping, PLN-R14Δ/Δ mice were 
randomly subjected to treatment with eplerenone or metoprolol or vehicle. Eplerenone (Inspra, 200 mg/kg/
day; Pfizer, NY, USA) was mixed with the chow as described elsewhere15. Metoprolol (350 mg/kg/day; M5391 
Sigma-Aldrich) was dissolved in the drinking water as reported elsewhere45. Drug administration was initiated 
at weaning (3 weeks of age) when cardiac abnormalities were still absent in PLN-R14Δ/Δ mice (Supplementary 
Fig. S1), and was continued until the endpoint was reached.
Figure 6. Graphical abstract. PLN-R14Δ/Δ mice (left) mimic human disease in a strikingly comparable but 
accelerated manner, evidenced by cardiac dilatation, contractile dysfunction, decreased ECG potentials, 
high susceptibility to ex vivo induced arrhythmias, cardiac fibrosis, PLN protein aggregation, and early 
mortality. Administration of standard HF therapy could not rescue the phenotype. PLN-R14Δ/+ mice (right) 
demonstrated increased susceptibility to ex vivo induced arrhythmias, and developed cardiomyopathy with 
comparable characteristics at middle age, similar to human carriers. The phenotype was not accelerated by 
β-adrenergic stimulation.
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Sacrifice. PLN-R14Δ/+ mice and WT controls were sacrificed at the age of 20 months. PLN-R14Δ/Δ mice were 
sacrificed when they reached the endpoint. The endpoint is determined by presence of lethargy, dyspnoea and 
severe weight loss due to HF. During survival monitoring, it was observed that this occurred between 7 and 9 
weeks of age. Euthanasia was performed as previously reported46.
Ex vivo optical action potential recording and electrical stimulation. Hearts were excised, cannu-
lated, and perfused using a Langendorff setup as described elsewhere47. Ex vivo ECGs were recorded (Biosemi, 
the Netherlands) and analysed using LabChart Pro software (version 8; ADInstruments). Optical action poten-
tials were recorded with a CMOS camera (MiCAM05; SciMedia, CA, USA) using voltage-sensitive dye RH237 
(Invitrogen). Conduction velocity was calculated at basic stimulation interval of 120 ms using dF/dtmax as local 
moment of activation. Arrhythmias were induced by decreasing basic stimulation interval with steps of 5 ms for 
a period of 20 s until arrhythmias occurred or the ventricle failed to capture.
Histological analysis. Formalin-fixed cardiac transverse mid-slices were dehydrated, embedded in par-
affin (Klinipath, the Netherlands), and cut into 4-μm thick sections. Masson’s trichrome stain was performed 
to detect collagen deposition as a measurement of fibrosis as previously described48. Immunofluorescent stain-
ing was performed using an anti-PLN antibody (#MA3-922, Invitrogen) labelled with Alexa Fluor 555 (red) 
using an APEX antibody labelling kit (Invitrogen). Sections were co-stained with fluorescein isothiocyanate 
(FITC)-conjugated wheat germ agglutinin (WGA; Sigma-Aldrich) to stain extracellular matrix green, and DAPI 
(Vector Laboratories, CA, USA) to stain nuclei blue as previously reported49.
Quantitative PCR. Total RNA was isolated from tissues using TRI Reagent (Sigma-Aldrich), and cDNA 
synthesis was performed using the QuantiTect RT kit (Qiagen). Gene expression levels were determined by qPCR 
analysis using iQ SYBR green supermix (Bio-Rad, CA, USA) as previously described50. Gene expression was 
quantified by correcting for reference gene values of ribosomal protein lateral stalk subunit P0 (Rplp0, encoding 
36B4) using CFX Manager software (version 3.0; Bio-Rad), and the calculated values were expressed relative to 
the control group per experiment. Primer sequences can be found in Supplementary Table S1.
Western blot. Total protein was isolated from LV tissue using RIPA lysis buffer as previously described41. 
To obtain soluble and insoluble fractions, protein samples were centrifuged at 12,000 g for 10 min at 4 °C. The 
supernatant was collected and was considered the soluble fraction. The remaining pellet was dissolved in urea 
solution (8 M) and was considered the insoluble fraction. Protein concentrations were determined using a Pierce 
bicinchoninic acid (BCA) protein assay kit (Thermo Scientific, MA, USA) according to the manufacturer’s pro-
tocol. Equal amounts of protein (5 μg) were denatured, separated by gel electrophoresis using Novex 10–20% 
Tricine Protein Gels (Invitrogen), and transferred onto Immun-Blot polyvinylidene fluoride (PVDF) membranes 
(Bio-Rad). After overnight incubation at 4 °C with a primary antibody, membranes were incubated with an appro-
priate horseradish peroxide (HRP)-linked secondary antibody, and detection was performed using Western 
Lightning Ultra enhanced chemiluminescence (ECL; PerkinElmer, MA, USA) and an ImageQuant LAS 4000 
digital imaging system (GE Healthcare, IL, USA). Antibodies that were used are described in Supplementary 
Tables S2 and S3.
Statistical analysis. All data are presented as mean ± standard error of the mean (S.E.M.). For statistical 
analysis of survival curves, a log-rank test was performed. Arrhythmia incidence was tested using a χ2 test. For 
data with parametric distribution according to Shapiro-Wilk test for normality, and homogeneity of variance 
according to Levene’s test for homogeneity of variances, a two-tailed Student’s t-test was performed for compari-
sons between two groups, while for multi-group comparisons a one-way analysis of variance (ANOVA) followed 
by Tukey’s post-hoc test was performed. For data without parametric distribution or homogeneity of variance, a 
Mann-Whitney U test was performed. We considered small sample sizes (n < 10) insufficient to test for paramet-
ric distribution or homogeneity of variance. A P-value < 0.05 was considered statistically significant. All statisti-
cal analyses were performed using SPSS Statistics software (version 23; IBM, NY, USA).
Data availability
The datasets generated and/or analysed during the current study are available from the corresponding author on 
reasonable request.
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